Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17902991 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL12283739 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL13436631 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL14012280 | 1.00 | CTSS (0.52) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23998665 | 0.97 | CTSS (0.51) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL23106074 | 0.92 | CTSK (0.50) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL29593613 | 0.91 | CTSK (0.53) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL25459969 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL17209941 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA | |
| SCHEMBL28342732 | 0.90 | CTSK (0.48) | CTSSCTSKMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2024-11-26 | — | — | US | disclosed |
| US-20230317700-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-10-05 | — | — | US | disclosed |
| US-11591405-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-02-28 | — | — | US | disclosed |
| EP-4029873-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | Zymeworks Inc. (CA) | 2022-07-20 | — | — | EP | disclosed |
| EP-3194421-B1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2021-11-03 | — | — | EP | disclosed |
| CN-113416229-A | Cytotoxic and antimitotic compounds, and methods of use thereof | 酵活有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-107001415-B | Cytotoxic and antimitotic compounds, and methods of use thereof | 酵活有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20200207865-A2 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2020-07-02 | — | — | US | disclosed |
| US-20190345254-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS INC (CA) | 2019-11-14 | — | — | US | disclosed |
| US-10450378-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2019-10-22 | — | — | US | disclosed |
| US-10414822-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2019-09-17 | — | — | US | disclosed |
| US-20180208667-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2018-07-26 | — | — | US | disclosed |
| US-9879086-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS INC. (CA) | 2018-01-30 | — | — | US | disclosed |
| US-20170247408-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2017-08-31 | — | — | US | disclosed |
| EP-3194421-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | Zymeworks, Inc. (CA) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016041082-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CDRD Ventures, Inc. (CA) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075735-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-20190345254-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-20170247408-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-20200207865-A2 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-11591405-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-12152083-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-10414822-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-10450378-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
| US-20180208667-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | CTSS 834/4885CTSK 1063/4885MEN1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.